scispace - formally typeset
Search or ask a question
Institution

Rhône-Poulenc

About: Rhône-Poulenc is a based out in . It is known for research contribution in the topics: Alkyl & Catalysis. The organization has 8909 authors who have published 8934 publications receiving 182241 citations. The organization is also known as: Rhone-Poulenc.


Papers
More filters
Journal ArticleDOI
Lisa Ruby Basara1
TL;DR: Assessment of the relationship between existence of an informational DTCA campaign for a newly-marketed prescription medication and new prescription volume suggested that D TCA was effective in generating new prescriptions while the campaign was in effect, with residual but declining effects after discontinuation.
Abstract: Direct-to-consumer advertising (DTCA) of prescription medications is one manifestation of the growing significance that pharmaceutical companies attribute to patients. Because most studies of DTCA ...

53 citations

Journal ArticleDOI
TL;DR: It is indicated that pyrithiobac can effectively control Palmer amaranth and devil's-claw in cotton on the Texas Southern High Plains when applied at appropriate rates and timings.
Abstract: Field experiments conducted in 1991, 1992, and 1993 evaluated Palmer amaranth and devil's-claw control and cotton injury with pyrithiobac applied PPI, PRE, or POST. Pyrithiobac at 36 or 71 g ae/ha applied PPI, PRE, or POST did not injure cotton. Pyrithiobac at 140 g/ha applied PPI or PRE injured cotton 9 to 11% 6 wk after treatment. Cotton recovered and no injury was observed 12 wk after treatment. Pyrithiobac applied PPI and PRE at 71 g/ha controlled Palmer amaranth at least 97% 6 wk after treatment. Palmer amaranth control with pyrithiobac applied POST was more variable and influenced by environmental conditions. Palmer amaranth control with 71 g/ha of pyrithiobac exceeded that with 36 g/ha. Devil's-claw control with pyrithiobac was better with POST applications than PPI or PRE applications. Pyrithiobac applied POST at 140 g/ha controlled devil's-claw 83-97%. These studies indicate that pyrithiobac can effectively control Palmer amaranth and devil's-claw in cotton on the Texas Southern High Plains when applied at appropriate rates and timings.

53 citations

Journal ArticleDOI
TL;DR: The interactions of surfactant-stabilized PLA and PLA-PEO nanoparticle suspensions with the plasma factors of the coagulation system are presented and Steric repulsion owing to the high surface density of PEO is sufficient to avoid strong interations with the proteins and formation of aggregates between particles.

53 citations

Journal Article
TL;DR: Because of its availability, due to an efficient process using a renewable source of natural precursor, its preclinical profile (higher antitumoral activity than taxol with a comparable toxicological profile) and its unique mechanism of action, Taxotere has entered Phase I clinical trials in Europe, United States and Japan.
Abstract: Taxotere [N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl taxol] is a new chemical entity obtained by semisynthesis from 10-deacetylbaccatin III, a non cytotoxic precursor extracted from the needles of the European yew Taxus baccata. Taxotere retains the unique mechanism of action of taxol and inhibits the depolymerisation of microtubules into tubulin. In vitro, Taxotere is cytotoxic against murine and human tumor cells with IC50 values ranging from 4 to 35 ng/ml. Taxotere inhibits the clonogenic properties of fresh human tumor cells at clinically relevant concentrations. Taxotere is highly active in vivo against several experimental models: it is 2.7-fold more active than taxol on a log cell kill basis against B16 melanoma; ten out of the twelve models of grafted murine tumors tested respond to Taxotere; it is active with 80% complete regressions against advanced C38 colon adenocarcinoma and PO3 pancreatic ductal adenocarcinoma. Finally, Taxotere is active against several human xenografts implanted in nude mice. Safety studies were performed in dogs and mice according to NCI guidelines. Toxicological effects are observed mostly is tissues with high cell turnover (bone marrow in mice and dogs, gastrointestinal tract in dogs only) or in those where microtubules play an important role (peripheral nerves in mice only). Because of its availability, due to an efficient process using a renewable source of natural precursor, its preclinical profile (higher antitumoral activity than taxol with a comparable toxicological profile) and its unique mechanism of action, Taxotere has entered Phase I clinical trials in Europe, United States and Japan. The dose limiting toxicity is a neutropenia. Evidence of clinical activity has been noted (breast, ovarian, lung). Taxotere is now in Phase II clinical trials.

53 citations

Journal ArticleDOI
TL;DR: Les proprietes structurales (cristallinite, orientation amorphe, birefringence axiale et plane) le long du chemin de deformation augmentent avec le taux d'etirage, a taux de tirage donne, elles augmentent augmenting aussi avec the force d'tirage.
Abstract: Les proprietes structurales (cristallinite, orientation amorphe, birefringence axiale et plane) le long du chemin de deformation augmentent avec le taux d'etirage, a taux d'etirage donne, elles augmentent aussi avec la force d'etirage. La temperature d'etirage est le facteur principal controlant l'orientation des chaines

53 citations


Authors

Showing all 8909 results

NameH-indexPapersCitations
Bart Staels15282486638
Joseph Schlessinger15049298862
Jean-Marie Lehn123105484616
Angus C. Nairn11846944330
Allan I. Basbaum11435555532
Patrick Couvreur11167856735
Joël Vandekerckhove10745238241
Jules A. Hoffmann10624443596
Johan Richard9549925915
Jacques Mallet8140824502
Roland Douce8028418239
David Givol8026020057
Jean-Antoine Girault7724619592
Michel Perricaudet7629620063
Jean-Marie Basset7573723390
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

89% related

Bristol-Myers Squibb
21K papers, 932.5K citations

88% related

GlaxoSmithKline
21.1K papers, 1.1M citations

87% related

Novartis
50.5K papers, 1.9M citations

87% related

Eli Lilly and Company
22.8K papers, 946.7K citations

87% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20201
20161
20119
201024
20095
20081